BR0111188A - Inibidores de adesão de célula mediada por alfal beta2 - Google Patents

Inibidores de adesão de célula mediada por alfal beta2

Info

Publication number
BR0111188A
BR0111188A BR0111188-4A BR0111188A BR0111188A BR 0111188 A BR0111188 A BR 0111188A BR 0111188 A BR0111188 A BR 0111188A BR 0111188 A BR0111188 A BR 0111188A
Authority
BR
Brazil
Prior art keywords
cell adhesion
mediated cell
adhesion inhibitors
beta
alpha2
Prior art date
Application number
BR0111188-4A
Other languages
English (en)
Inventor
Ila Sircar
Yun Feng Xie
Nicholas Smith
Paul S Furth
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BR0111188A publication Critical patent/BR0111188A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"INIBIDORES DE ADESãO DE CéLULA MEDIADA POR ALFA~ L~BETA~ 2~". A presente invenção refere-se a pequenas moléculas de acordo com a fórmula (I) que são potentes inibidores de adesão de célula mediada por <244>~ L~<225>~ 2~ e que podem ser úteis para o tratamento de doenças inflamatórias.
BR0111188-4A 2000-05-31 2001-04-17 Inibidores de adesão de célula mediada por alfal beta2 BR0111188A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20796800P 2000-05-31 2000-05-31
PCT/US2001/012323 WO2001092253A2 (en) 2000-05-31 2001-04-17 Inhibitors of alpha l beta 2 mediated cell adhesion

Publications (1)

Publication Number Publication Date
BR0111188A true BR0111188A (pt) 2003-06-10

Family

ID=22772705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111188-4A BR0111188A (pt) 2000-05-31 2001-04-17 Inibidores de adesão de célula mediada por alfal beta2

Country Status (19)

Country Link
US (1) US6699888B2 (pt)
EP (1) EP1284973B1 (pt)
JP (1) JP3924531B2 (pt)
KR (1) KR100527290B1 (pt)
CN (1) CN1209358C (pt)
AT (1) ATE365729T1 (pt)
AU (2) AU2001253538B2 (pt)
BR (1) BR0111188A (pt)
CA (1) CA2411671C (pt)
CY (1) CY1106843T1 (pt)
DE (1) DE60129132T2 (pt)
DK (1) DK1284973T3 (pt)
ES (1) ES2284641T3 (pt)
HK (1) HK1051370A1 (pt)
IL (1) IL152961A0 (pt)
MX (1) MXPA02011858A (pt)
NZ (1) NZ522852A (pt)
PT (1) PT1284973E (pt)
WO (1) WO2001092253A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007444A2 (en) 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2006082834A1 (ja) * 2005-02-02 2006-08-10 Kowa Co., Ltd. ケラチノサイト増殖に起因する疾患の予防・治療剤
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
DK2368550T3 (da) 2006-03-27 2013-09-30 Univ California Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
UY31432A1 (es) * 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
SG10201501202TA (en) 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US6350763B1 (en) * 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease

Also Published As

Publication number Publication date
CN1209358C (zh) 2005-07-06
WO2001092253A3 (en) 2002-05-23
HK1051370A1 (en) 2003-08-01
CN1432007A (zh) 2003-07-23
ES2284641T3 (es) 2007-11-16
DK1284973T3 (da) 2007-10-08
CA2411671A1 (en) 2001-12-06
JP2003535087A (ja) 2003-11-25
AU2001253538B2 (en) 2004-03-04
KR20030015235A (ko) 2003-02-20
MXPA02011858A (es) 2004-07-30
CY1106843T1 (el) 2012-05-23
CA2411671C (en) 2007-06-05
ATE365729T1 (de) 2007-07-15
JP3924531B2 (ja) 2007-06-06
DE60129132D1 (de) 2007-08-09
PT1284973E (pt) 2007-08-17
DE60129132T2 (de) 2008-02-28
NZ522852A (en) 2004-09-24
EP1284973A2 (en) 2003-02-26
EP1284973B1 (en) 2007-06-27
AU5353801A (en) 2001-12-11
KR100527290B1 (ko) 2005-11-09
IL152961A0 (en) 2003-06-24
US6699888B2 (en) 2004-03-02
WO2001092253A2 (en) 2001-12-06
US20030225138A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
BR0111188A (pt) Inibidores de adesão de célula mediada por alfal beta2
DK0991619T3 (da) Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
BR0012666A (pt) Imidazoimidazóis e triazóis como agentes anti-inflamatórios
BR0307960A (pt) N-aminoacetil-pirrolidina-2-carbonitrilas e seu uso como inibidores de ddp-iv
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
EA200802213A1 (ru) Способы лечения заболеваний крови
BR9813022A (pt) Derivados de ésteres hidroxiacéticos, seu processo de preparação e sua utilização como intermediários de sìntese
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
BR9916638A (pt) Compostos anti-inflamatórios e imuno-supressores inibidores de aderência celular
ATE381531T1 (de) Nitroderivate als arzneimittel für auf entzündungen beruhende erkrankungen
BR0317857A (pt) Tratamento de anorexia nervosa (an) e bulimia
TW200407133A (en) Novel PPARα and PPARγ agonists
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
NO984950D0 (no) Forbindelser med veksthormonfrigj°rende egenskaper
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
DE69702182D1 (de) Alkylierte styrole als prodrugs zu cox-2-inhibitoren
SE0004101D0 (sv) New use
BR9508342A (pt) Compostos orgânicos
AP2000001760A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
ES2169399T3 (es) Procedimiento para preparar heterociclos de fenilo utiles como inhibidores de la cox-2.
BRPI0417140A (pt) derivados quinolina ácidos e seu uso na prevenção e/ou tratamento de patologias relacionadas com hiperglicemia
UY26179A1 (es) Amidas sustituidas del ácido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporación de adenosina.
HUP9902417A2 (hu) Alfa-ketoészterek, és alfa-ketoamidok acilezett enol-származékai
BR0317445A (pt) Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.